vs
ANGIODYNAMICS INC（ANGO）与Penumbra Inc（PEN）财务数据对比。点击上方公司名可切换其他公司
Penumbra Inc的季度营收约是ANGIODYNAMICS INC的4.9倍（$385.4M vs $79.4M）。Penumbra Inc净利率更高（12.3% vs -8.0%，领先20.3%）。Penumbra Inc同比增速更快（22.1% vs 9.0%）。Penumbra Inc自由现金流更多（$68.0M vs $4.2M）。过去两年Penumbra Inc的营收复合增速更高（17.6% vs 2.8%）
AngioDynamics是一家全球医疗技术企业，专注于研发、生产及销售微创医疗设备，核心产品覆盖血管通路、外科消融、肿瘤治疗等领域，面向北美、欧洲、亚太地区的医院、门诊手术中心及各类医疗机构提供服务。
Penumbra Inc是2004年由Arani Bose与Adam Elsesser联合创立的美国医疗器械企业，总部位于加利福尼亚州阿拉米达，核心业务为研发、生产中风、动脉瘤等血管疾病介入治疗所用的专业医疗设备，产品已在全球多个国家的临床诊疗场景中投入使用。
ANGO vs PEN — 直观对比
营收规模更大
PEN
是对方的4.9倍
$79.4M
营收增速更快
PEN
高出13.1%
9.0%
净利率更高
PEN
高出20.3%
-8.0%
自由现金流更多
PEN
多$63.8M
$4.2M
两年增速更快
PEN
近两年复合增速
2.8%
损益表 — Q2 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $79.4M | $385.4M |
| 净利润 | $-6.3M | $47.3M |
| 毛利率 | 56.4% | 68.0% |
| 营业利润率 | -7.7% | 15.4% |
| 净利率 | -8.0% | 12.3% |
| 营收同比 | 9.0% | 22.1% |
| 净利润同比 | 40.9% | 40.6% |
| 每股收益（稀释后） | $-0.15 | $1.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANGOPEN
| Q4 25 | $79.4M | $385.4M | ||
| Q3 25 | $75.7M | $354.7M | ||
| Q2 25 | $80.2M | $339.5M | ||
| Q1 25 | $72.0M | $324.1M | ||
| Q4 24 | $72.8M | $315.5M | ||
| Q3 24 | $67.5M | $301.0M | ||
| Q2 24 | $71.0M | $299.4M | ||
| Q1 24 | $75.2M | $278.7M |
净利润ANGOPEN
| Q4 25 | $-6.3M | $47.3M | ||
| Q3 25 | $-10.9M | $45.9M | ||
| Q2 25 | $-6.0M | $45.3M | ||
| Q1 25 | $-4.4M | $39.2M | ||
| Q4 24 | $-10.7M | $33.7M | ||
| Q3 24 | $-12.8M | $29.5M | ||
| Q2 24 | $-13.4M | $-60.2M | ||
| Q1 24 | $-187.7M | $11.0M |
毛利率ANGOPEN
| Q4 25 | 56.4% | 68.0% | ||
| Q3 25 | 55.3% | 67.8% | ||
| Q2 25 | 52.7% | 66.0% | ||
| Q1 25 | 54.0% | 66.6% | ||
| Q4 24 | 54.8% | 66.8% | ||
| Q3 24 | 54.4% | 66.5% | ||
| Q2 24 | 54.3% | 54.4% | ||
| Q1 24 | 47.7% | 65.0% |
营业利润率ANGOPEN
| Q4 25 | -7.7% | 15.4% | ||
| Q3 25 | -14.1% | 13.8% | ||
| Q2 25 | -7.2% | 12.0% | ||
| Q1 25 | -13.9% | 12.4% | ||
| Q4 24 | -15.2% | 13.6% | ||
| Q3 24 | -19.4% | 11.7% | ||
| Q2 24 | -20.4% | -27.0% | ||
| Q1 24 | -265.9% | 4.3% |
净利率ANGOPEN
| Q4 25 | -8.0% | 12.3% | ||
| Q3 25 | -14.4% | 12.9% | ||
| Q2 25 | -7.5% | 13.3% | ||
| Q1 25 | -6.1% | 12.1% | ||
| Q4 24 | -14.7% | 10.7% | ||
| Q3 24 | -19.0% | 9.8% | ||
| Q2 24 | -18.9% | -20.1% | ||
| Q1 24 | -249.7% | 3.9% |
每股收益（稀释后）ANGOPEN
| Q4 25 | $-0.15 | $1.20 | ||
| Q3 25 | $-0.26 | $1.17 | ||
| Q2 25 | $-0.15 | $1.15 | ||
| Q1 25 | $-0.11 | $1.00 | ||
| Q4 24 | $-0.26 | $0.88 | ||
| Q3 24 | $-0.31 | $0.75 | ||
| Q2 24 | $-0.35 | $-1.55 | ||
| Q1 24 | $-4.67 | $0.28 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $41.6M | $186.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $176.3M | $1.4B |
| 总资产 | $269.7M | $1.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANGOPEN
| Q4 25 | $41.6M | $186.9M | ||
| Q3 25 | $38.8M | $321.0M | ||
| Q2 25 | $55.9M | $421.8M | ||
| Q1 25 | $44.8M | $376.1M | ||
| Q4 24 | $54.1M | $324.4M | ||
| Q3 24 | $55.0M | $280.5M | ||
| Q2 24 | $76.1M | $288.3M | ||
| Q1 24 | $78.5M | $223.1M |
总债务ANGOPEN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | — | — |
股东权益ANGOPEN
| Q4 25 | $176.3M | $1.4B | ||
| Q3 25 | $178.9M | $1.4B | ||
| Q2 25 | $183.0M | $1.3B | ||
| Q1 25 | $185.9M | $1.2B | ||
| Q4 24 | $186.8M | $1.2B | ||
| Q3 24 | $196.6M | $1.1B | ||
| Q2 24 | $205.6M | $1.2B | ||
| Q1 24 | $218.7M | $1.2B |
总资产ANGOPEN
| Q4 25 | $269.7M | $1.8B | ||
| Q3 25 | $265.6M | $1.7B | ||
| Q2 25 | $280.1M | $1.7B | ||
| Q1 25 | $285.4M | $1.6B | ||
| Q4 24 | $291.6M | $1.5B | ||
| Q3 24 | $293.6M | $1.5B | ||
| Q2 24 | $317.7M | $1.5B | ||
| Q1 24 | $324.8M | $1.6B |
负债/权益比ANGOPEN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.7M | $86.5M |
| 自由现金流经营现金流 - 资本支出 | $4.2M | $68.0M |
| 自由现金流率自由现金流/营收 | 5.3% | 17.7% |
| 资本支出强度资本支出/营收 | 0.5% | 4.8% |
| 现金转化率经营现金流/净利润 | — | 1.83× |
| 过去12个月自由现金流最近4个季度 | $-9.3M | $174.9M |
8季度趋势，按日历期对齐
经营现金流ANGOPEN
| Q4 25 | $4.7M | $86.5M | ||
| Q3 25 | $-15.9M | $58.3M | ||
| Q2 25 | $18.8M | $44.9M | ||
| Q1 25 | $-13.2M | $49.0M | ||
| Q4 24 | $2.5M | $51.1M | ||
| Q3 24 | $-18.3M | $56.5M | ||
| Q2 24 | $5.0M | $22.6M | ||
| Q1 24 | $-12.5M | $38.3M |
自由现金流ANGOPEN
| Q4 25 | $4.2M | $68.0M | ||
| Q3 25 | $-16.6M | $42.0M | ||
| Q2 25 | $18.0M | $29.4M | ||
| Q1 25 | $-15.0M | $35.5M | ||
| Q4 24 | $1.7M | $45.7M | ||
| Q3 24 | $-19.3M | $51.0M | ||
| Q2 24 | $4.4M | $18.1M | ||
| Q1 24 | $-13.1M | $32.5M |
自由现金流率ANGOPEN
| Q4 25 | 5.3% | 17.7% | ||
| Q3 25 | -22.0% | 11.8% | ||
| Q2 25 | 22.5% | 8.7% | ||
| Q1 25 | -20.8% | 11.0% | ||
| Q4 24 | 2.3% | 14.5% | ||
| Q3 24 | -28.7% | 16.9% | ||
| Q2 24 | 6.2% | 6.0% | ||
| Q1 24 | -17.5% | 11.7% |
资本支出强度ANGOPEN
| Q4 25 | 0.5% | 4.8% | ||
| Q3 25 | 1.0% | 4.6% | ||
| Q2 25 | 1.0% | 4.6% | ||
| Q1 25 | 2.5% | 4.2% | ||
| Q4 24 | 1.1% | 1.7% | ||
| Q3 24 | 1.6% | 1.8% | ||
| Q2 24 | 0.8% | 1.5% | ||
| Q1 24 | 0.8% | 2.1% |
现金转化率ANGOPEN
| Q4 25 | — | 1.83× | ||
| Q3 25 | — | 1.27× | ||
| Q2 25 | — | 0.99× | ||
| Q1 25 | — | 1.25× | ||
| Q4 24 | — | 1.52× | ||
| Q3 24 | — | 1.91× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 3.48× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANGO
| Med Device | $37.2M | 47% |
| Med Tech | $30.4M | 38% |
| Other | $11.8M | 15% |
PEN
暂无分部数据
